文献速递临床试验与 GCP基础与转化研究

对乙酰氨基酚预防和治疗脓毒症危重患者器官功能障碍:ASTER随机临床试验

Acetaminophen for Prevention and Treatment of Organ Dysfunction in Critically Ill Patients With Sepsis: The ASTER Randomized Clinical Trial.
PubMed 文献 · JAMA · 2024-01-01

至第28天存活且无器官支持天数两组无显著差异(20.2天 vs 19.6天,P=0.56),对乙酰氨基酚安全性良好。

要点

  • 至第28天无器官支持存活天数对乙酰氨基酚组20.2天 vs 安慰剂组19.6天,差异无统计学意义(P=0.56)。
  • 第2至4天总SOFA、呼吸SOFA、凝血SOFA评分在对乙酰氨基酚组显著更低;7天内ARDS发生率2.2% vs 8.5%(P=0.01)。
  • 对乙酰氨基酚安全性良好,两组肝酶、低血压及液体平衡无差异。

核心结论

  • 静脉对乙酰氨基酚在脓毒症危重患者中安全,但未显著改善至第28天存活且无器官支持天数。

研究设计与样本

  • 2b期随机双盲安慰剂对照临床试验,2021年10月至2023年4月开展,随访90天;40家美国学术医院急诊科或ICU在就诊36小时内纳入脓毒症伴呼吸或循环器官功能障碍成人。
  • 共纳入447例(平均年龄64岁,标准差15;女性51%;平均SOFA评分5.4,标准差2.5),对乙酰氨基酚组227例,安慰剂组220例。
  • 干预为静脉对乙酰氨基酚1 g每6小时或安慰剂,共5天;主要终点为至第28天存活且无器官支持(机械通气、血管升压药、肾脏替代治疗)天数;按随机前血浆游离血红蛋白高于10 mg/dL评估效应修饰。

主要发现

  • 至第28天存活且无器官支持天数:对乙酰氨基酚组20.2天(95%CI 18.8至21.6)vs 安慰剂组19.6天(95%CI 18.2至21.0),P=0.56,差异0.6天(95%CI -1.4至2.6)。
  • 15项次要结局中,第2至4天总SOFA、呼吸SOFA和凝血SOFA评分在对乙酰氨基酚组显著更低。
  • 7天内急性呼吸窘迫综合征发生率对乙酰氨基酚组2.2% vs 安慰剂组8.5%(P=0.01;差异-6.3,95%CI -10.8至-1.8)。
  • 游离血红蛋白水平与对乙酰氨基酚之间无显著交互作用。
  • 对乙酰氨基酚安全性良好,两组肝酶、低血压或液体平衡无差异。

关键数值与推荐

  • 主要终点为至第28天存活且无器官支持天数,对乙酰氨基酚组20.2天(95%CI 18.8至21.6)vs 安慰剂组19.6天(95%CI 18.2至21.0),P=0.56。
  • 7天内急性呼吸窘迫综合征发生率对乙酰氨基酚组2.2% vs 安慰剂组8.5%(P=0.01;差异-6.3,95%CI -10.8至-1.8)。
  • 静脉对乙酰氨基酚剂量为1 g每6小时,共5天。

临床怎么用

  • 原文结论为静脉对乙酰氨基酚安全但未显著改善脓毒症危重患者存活且无器官支持天数,未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Acetaminophen (paracetamol) has many pharmacological effects that might be beneficial in sepsis, including inhibition of cell-free hemoglobin-induced oxidation of lipids and other substrates. OBJECTIVE: To determine whether acetaminophen increases days alive and free of organ dysfunction in sepsis compared with placebo. DESIGN, SETTING, AND PARTICIPANTS: Phase 2b randomized, double-blind, clinical trial conducted from October 2021 to April 2023 with 90-day follow-up. Adults with sepsis and respiratory or circulatory organ dysfunction were enrolled in the emergency department or intensive care unit of 40 US academic hospitals within 36 hours of presentation. INTERVENTION: Patients were randomized to 1 g of acetaminophen intravenously every 6 hours or placebo for 5 days. MAIN OUTCOME AND MEASURES: The primary end point was days alive and free of organ support (mechanical ventilation, vasopressors, and kidney replacement therapy) to day 28. Treatment effect modification was evaluated for acetaminophen by prerandomization plasma cell-free hemoglobin level higher than 10 mg/dL. RESULTS: Of 447 patients enrolled (mean age, 64 [SD, 15] years, 51% female, mean Sequential Organ Failure Assessment [SOFA] score, 5.4 [SD, 2.5]), 227 were randomized to acetaminophen and 220 to placebo. Acetaminophen was safe with no difference in liver enzymes, hypotension, or fluid balance between treatment arms. Days alive and free of organ support to day 28 were not meaningfully different for acetaminophen (20.2 days; 95% CI, 18.8 to 21.6) vs placebo (19.6 days; 95% CI, 18.2 to 21.0; P = .56; difference, 0.6; 95% CI, -1.4 to 2.6). Among 15 secondary outcomes, total, respiratory, and coagulation SOFA scores were significantly lower on days 2 through 4 in the acetaminophen arm as was the rate of development of acute respiratory distress syndrome within 7 days (2.2% vs 8.5% acetaminophen vs placebo; P = .01; difference, -6.3; 95% CI, -10.8 to -1.8). There was no significant interaction between cell-free hemoglobin levels and acetaminophen. CONCLUSIONS AND RELEVANCE: Intravenous acetaminophen was safe but did not significantly improve days alive and free of organ support in critically ill sepsis patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04291508.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Ware LB, Files DC, Fowler A, et al. Acetaminophen for Prevention and Treatment of Organ Dysfunction in Critically Ill Patients With Sepsis: The ASTER Randomized Clinical Trial. JAMA. 2024. PMID: 38762798. doi:10.1001/jama.2024.8772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。